Drug Profile
Research programme: bispecific antibodies - Micromet/Sanofi
Alternative Names: Cancer therapy - Micromet/SanofiLatest Information Update: 30 Jul 2012
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Micromet Inc; Sanofi
- Class Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Jul 2012 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
- 07 Mar 2012 Micromet Inc has been acquired by Amgen
- 02 Mar 2012 Preclinical trials in Solid tumours in USA (Parenteral)